Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
BRIEF-Nvidia Guarantees Sb Energy's Ports-Pike Technology Campus In Ohio To Exclusively Host Nvidia Ai Compute

BRIEF-Nvidia Guarantees Sb Energy's Ports-Pike Technology Campus In Ohio To Exclusively Host Nvidia Ai Compute

ReutersReuters2026/08/17 12:36

NVIDIA Corp NVDA.O:

  • NVIDIA GUARANTEES SB ENERGY'S PORTS-PIKE TECHNOLOGY CAMPUS IN OHIO TO EXCLUSIVELY HOST NVIDIA AI COMPUTE

  • NVIDIA CORP - TO PROVIDE CREDIT SUPPORT FOR INITIAL 4.25 IT-GW, OPTION FOR 3.75 IT-GW MORE

  • NVIDIA CORP - TO INVEST $1.50 BILLION IN SB ENERGY

  • NVIDIA CORP - OPENAI TO BE CUSTOMER FOR 8 IT-GW AT PORTS-PIKE

  • NVIDIA CORP - PORTS-PIKE PROJECT TO CREATE TENS OF THOUSANDS OF JOBS, $80 MILLION COMMUNITY FUND

  • NVIDIA CORP - OPENAI TO CONTRIBUTE ADDITIONAL $40 MILLION TO COMMUNITY BENEFITS FUND

  • NVIDIA CORP - SB ENERGY, SOFTBANK TO BUILD 10 GW ENERGY, INVEST $4.20 BILLION IN GRID INFRASTRUCTURE

  • NVIDIA CORP - SB ENERGY TO OPERATE DATA CENTER UNDER 20-YEAR LEASE TO OPENAI

Source text: ID:nGNX6DXDWh

Further company coverage: NVDA.O


0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds